Cargando…

Tecovirimat for the treatment of severe Mpox in Germany

BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermanussen, Lennart, Brehm, Thomas Theo, Wolf, Timo, Boesecke, Christoph, Schlabe, Stefan, Borgans, Frauke, Monin, Malte B., Jensen, Björn-Erik Ole, Windhaber, Stefan, Scholten, Stefan, Jordan, Sabine, Lütgehetmann, Marc, Wiesch, Julian Schulze zur, Addo, Marylyn M., Mikolajewska, Agata, Niebank, Michaela, Schmiedel, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240449/
https://www.ncbi.nlm.nih.gov/pubmed/37273167
http://dx.doi.org/10.1007/s15010-023-02049-0
_version_ 1785053755057635328
author Hermanussen, Lennart
Brehm, Thomas Theo
Wolf, Timo
Boesecke, Christoph
Schlabe, Stefan
Borgans, Frauke
Monin, Malte B.
Jensen, Björn-Erik Ole
Windhaber, Stefan
Scholten, Stefan
Jordan, Sabine
Lütgehetmann, Marc
Wiesch, Julian Schulze zur
Addo, Marylyn M.
Mikolajewska, Agata
Niebank, Michaela
Schmiedel, Stefan
author_facet Hermanussen, Lennart
Brehm, Thomas Theo
Wolf, Timo
Boesecke, Christoph
Schlabe, Stefan
Borgans, Frauke
Monin, Malte B.
Jensen, Björn-Erik Ole
Windhaber, Stefan
Scholten, Stefan
Jordan, Sabine
Lütgehetmann, Marc
Wiesch, Julian Schulze zur
Addo, Marylyn M.
Mikolajewska, Agata
Niebank, Michaela
Schmiedel, Stefan
author_sort Hermanussen, Lennart
collection PubMed
description BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus. METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms. RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.
format Online
Article
Text
id pubmed-10240449
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102404492023-06-06 Tecovirimat for the treatment of severe Mpox in Germany Hermanussen, Lennart Brehm, Thomas Theo Wolf, Timo Boesecke, Christoph Schlabe, Stefan Borgans, Frauke Monin, Malte B. Jensen, Björn-Erik Ole Windhaber, Stefan Scholten, Stefan Jordan, Sabine Lütgehetmann, Marc Wiesch, Julian Schulze zur Addo, Marylyn M. Mikolajewska, Agata Niebank, Michaela Schmiedel, Stefan Infection Brief Report BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus. METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms. RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement. Springer Berlin Heidelberg 2023-06-05 2023 /pmc/articles/PMC10240449/ /pubmed/37273167 http://dx.doi.org/10.1007/s15010-023-02049-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Report
Hermanussen, Lennart
Brehm, Thomas Theo
Wolf, Timo
Boesecke, Christoph
Schlabe, Stefan
Borgans, Frauke
Monin, Malte B.
Jensen, Björn-Erik Ole
Windhaber, Stefan
Scholten, Stefan
Jordan, Sabine
Lütgehetmann, Marc
Wiesch, Julian Schulze zur
Addo, Marylyn M.
Mikolajewska, Agata
Niebank, Michaela
Schmiedel, Stefan
Tecovirimat for the treatment of severe Mpox in Germany
title Tecovirimat for the treatment of severe Mpox in Germany
title_full Tecovirimat for the treatment of severe Mpox in Germany
title_fullStr Tecovirimat for the treatment of severe Mpox in Germany
title_full_unstemmed Tecovirimat for the treatment of severe Mpox in Germany
title_short Tecovirimat for the treatment of severe Mpox in Germany
title_sort tecovirimat for the treatment of severe mpox in germany
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240449/
https://www.ncbi.nlm.nih.gov/pubmed/37273167
http://dx.doi.org/10.1007/s15010-023-02049-0
work_keys_str_mv AT hermanussenlennart tecovirimatforthetreatmentofseverempoxingermany
AT brehmthomastheo tecovirimatforthetreatmentofseverempoxingermany
AT wolftimo tecovirimatforthetreatmentofseverempoxingermany
AT boeseckechristoph tecovirimatforthetreatmentofseverempoxingermany
AT schlabestefan tecovirimatforthetreatmentofseverempoxingermany
AT borgansfrauke tecovirimatforthetreatmentofseverempoxingermany
AT moninmalteb tecovirimatforthetreatmentofseverempoxingermany
AT jensenbjornerikole tecovirimatforthetreatmentofseverempoxingermany
AT windhaberstefan tecovirimatforthetreatmentofseverempoxingermany
AT scholtenstefan tecovirimatforthetreatmentofseverempoxingermany
AT jordansabine tecovirimatforthetreatmentofseverempoxingermany
AT lutgehetmannmarc tecovirimatforthetreatmentofseverempoxingermany
AT wieschjulianschulzezur tecovirimatforthetreatmentofseverempoxingermany
AT addomarylynm tecovirimatforthetreatmentofseverempoxingermany
AT mikolajewskaagata tecovirimatforthetreatmentofseverempoxingermany
AT niebankmichaela tecovirimatforthetreatmentofseverempoxingermany
AT schmiedelstefan tecovirimatforthetreatmentofseverempoxingermany